Drugmakers Are Vying for a Multibillion-Dollar Market

Brian Orelli, PhD and Keith Speights, The Motley Fool
·3-min read

Autoimmune diseases, such as rheumatoid arthritis, atopic dermatitis, and psoriatic arthritis, offer a multibillion-dollar opportunity for JAK inhibitors. In this video from Motley Fool Live, recorded on March 22, Fool.com contributors Brian Orelli and Keith Speights discuss the JAK inhibitors under development and which ones might be the safest bet given the Food and Drug Administration's crackdown on the drug class.